Loading clinical trials...
Loading clinical trials...
A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)
Conditions
Interventions
Norketotifen
Placebo
Locations
20
United States
Precision Trials AZ
Phoenix, Arizona, United States
Downtown LA Research Center
Los Angeles, California, United States
Omega Research Debary
DeBary, Florida, United States
The Chappel Group Research
Kissimmee, Florida, United States
South Florida Research Center
Miami, Florida, United States
Premier Research Associate
Miami, Florida, United States
Start Date
December 14, 2020
Primary Completion Date
January 25, 2022
Completion Date
February 9, 2022
Last Updated
January 30, 2023
NCT01386424
NCT07169318
NCT07291635
NCT06599658
NCT06094010
NCT06753474
Lead Sponsor
Emergo Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions